A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma

Background: Novel therapies for multiple myeloma (MM) promise to improve outcomes but are also associated with substantial increasing costs. Evidence regarding cost-effectiveness of novel treatments is necessary, but a comprehensive up-to-date overview of the cost-effectiveness evidence of novel tre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maarten R. Seefat, David G. J. Cucchi, Stijn Dirven, Kaz Groen, Sonja Zweegman, Hedwig M. Blommestein
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	cost-effectiveness multiple myeloma economic evaluation daratumumab carfilzomib pomalidomide Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3e3da36cf816463da7d0e086f3846c0e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3e3da36cf816463da7d0e086f3846c0e
record_format	dspace
spelling	oai:doaj.org-article:3e3da36cf816463da7d0e086f3846c0e2021-11-25T17:01:25ZA Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma10.3390/cancers132256062072-6694https://doaj.org/article/3e3da36cf816463da7d0e086f3846c0e2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5606https://doaj.org/toc/2072-6694Background: Novel therapies for multiple myeloma (MM) promise to improve outcomes but are also associated with substantial increasing costs. Evidence regarding cost-effectiveness of novel treatments is necessary, but a comprehensive up-to-date overview of the cost-effectiveness evidence of novel treatments is currently lacking. Methods: We searched Embase, Medline via Ovid, Web of Science and EconLIT ProQuest to identify all cost-effectiveness evaluations of novel pharmacological treatment of MM reporting cost per quality-adjusted life year (QALY) and cost per life year (LY) gained since 2005. Quality and completeness of reporting was assessed using the Consolidated Health Economic Evaluation Reporting Standards. Results: We identified 13 economic evaluations, comprising 32 comparisons. Our results show that novel agents generate additional LYs (range: 0.311–3.85) and QALYs (range: 0.1–2.85) compared to backbone regimens and 0.02 to 1.10 LYs and 0.01 to 0.91 QALYs for comparisons between regimens containing two novel agents. Lifetime healthcare costs ranged from USD 60,413 to 1,434,937 per patient. The cost-effectiveness ratios per QALY gained ranged from dominating to USD 1,369,062 for novel agents compared with backbone therapies and from dominating to USD 618,018 for comparisons between novel agents. Conclusions: Cost-effectiveness ratios of novel agents were generally above current willingness-to-pay thresholds. To ensure access, cost-effectiveness should be improved or cost-effectiveness ratios above current thresholds should be accepted.Maarten R. SeefatDavid G. J. CucchiStijn DirvenKaz GroenSonja ZweegmanHedwig M. BlommesteinMDPI AGarticlecost-effectivenessmultiple myelomaeconomic evaluationdaratumumabcarfilzomibpomalidomideNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5606, p 5606 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cost-effectiveness multiple myeloma economic evaluation daratumumab carfilzomib pomalidomide Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cost-effectiveness multiple myeloma economic evaluation daratumumab carfilzomib pomalidomide Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maarten R. Seefat David G. J. Cucchi Stijn Dirven Kaz Groen Sonja Zweegman Hedwig M. Blommestein A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
description	Background: Novel therapies for multiple myeloma (MM) promise to improve outcomes but are also associated with substantial increasing costs. Evidence regarding cost-effectiveness of novel treatments is necessary, but a comprehensive up-to-date overview of the cost-effectiveness evidence of novel treatments is currently lacking. Methods: We searched Embase, Medline via Ovid, Web of Science and EconLIT ProQuest to identify all cost-effectiveness evaluations of novel pharmacological treatment of MM reporting cost per quality-adjusted life year (QALY) and cost per life year (LY) gained since 2005. Quality and completeness of reporting was assessed using the Consolidated Health Economic Evaluation Reporting Standards. Results: We identified 13 economic evaluations, comprising 32 comparisons. Our results show that novel agents generate additional LYs (range: 0.311–3.85) and QALYs (range: 0.1–2.85) compared to backbone regimens and 0.02 to 1.10 LYs and 0.01 to 0.91 QALYs for comparisons between regimens containing two novel agents. Lifetime healthcare costs ranged from USD 60,413 to 1,434,937 per patient. The cost-effectiveness ratios per QALY gained ranged from dominating to USD 1,369,062 for novel agents compared with backbone therapies and from dominating to USD 618,018 for comparisons between novel agents. Conclusions: Cost-effectiveness ratios of novel agents were generally above current willingness-to-pay thresholds. To ensure access, cost-effectiveness should be improved or cost-effectiveness ratios above current thresholds should be accepted.
format	article
author	Maarten R. Seefat David G. J. Cucchi Stijn Dirven Kaz Groen Sonja Zweegman Hedwig M. Blommestein
author_facet	Maarten R. Seefat David G. J. Cucchi Stijn Dirven Kaz Groen Sonja Zweegman Hedwig M. Blommestein
author_sort	Maarten R. Seefat
title	A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
title_short	A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
title_full	A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
title_fullStr	A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
title_full_unstemmed	A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
title_sort	systematic review of cost-effectiveness analyses of novel agents in the treatment of multiple myeloma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/3e3da36cf816463da7d0e086f3846c0e
work_keys_str_mv	AT maartenrseefat asystematicreviewofcosteffectivenessanalysesofnovelagentsinthetreatmentofmultiplemyeloma AT davidgjcucchi asystematicreviewofcosteffectivenessanalysesofnovelagentsinthetreatmentofmultiplemyeloma AT stijndirven asystematicreviewofcosteffectivenessanalysesofnovelagentsinthetreatmentofmultiplemyeloma AT kazgroen asystematicreviewofcosteffectivenessanalysesofnovelagentsinthetreatmentofmultiplemyeloma AT sonjazweegman asystematicreviewofcosteffectivenessanalysesofnovelagentsinthetreatmentofmultiplemyeloma AT hedwigmblommestein asystematicreviewofcosteffectivenessanalysesofnovelagentsinthetreatmentofmultiplemyeloma AT maartenrseefat systematicreviewofcosteffectivenessanalysesofnovelagentsinthetreatmentofmultiplemyeloma AT davidgjcucchi systematicreviewofcosteffectivenessanalysesofnovelagentsinthetreatmentofmultiplemyeloma AT stijndirven systematicreviewofcosteffectivenessanalysesofnovelagentsinthetreatmentofmultiplemyeloma AT kazgroen systematicreviewofcosteffectivenessanalysesofnovelagentsinthetreatmentofmultiplemyeloma AT sonjazweegman systematicreviewofcosteffectivenessanalysesofnovelagentsinthetreatmentofmultiplemyeloma AT hedwigmblommestein systematicreviewofcosteffectivenessanalysesofnovelagentsinthetreatmentofmultiplemyeloma
_version_	1718412770315075584

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma

Ejemplares similares